Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.
Open Access
- 1 January 1995
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 181 (1) , 381-386
- https://doi.org/10.1084/jem.181.1.381
Abstract
Experimental allergic encephalomyelitis (EAE) is an autoimmune disease of the central nervous system that can be transferred to naive mice via CD4+ T cells isolated from appropriately immunized mice. We have evaluated the effects of recombinant murine interleukin 12 (rmIL-12), a potent inducer of interferon gamma (IFN-gamma) and promoter of Th1 T cell development, on the course of adoptively transferred EAE. The transfer of lymph node cells (LNC) isolated from proteolipid protein (PLP)-primed animals and stimulated in vitro with PLP to naive mice resulted in a progressive paralytic disease culminating in complete hind limb paralysis in the majority of the recipients. When mice were injected with LNC that had been stimulated in vitro with PLP in the presence of rmIL-12, the subsequent course of disease was more severe and prolonged. The addition of rmIL-12 during the in vitro stimulation with PLP resulted in a 10-fold increase in IFN-gamma and a 2-fold increase in tumor necrosis factor (TNF) alpha in the supernatants, relative to LNC stimulated with PLP alone. However, neutralization of IFN-gamma or TNF-alpha in vitro with specific antibodies did not abrogate the ability of rmIL-12 to exacerbate the subsequent disease. Similarly, mice treated with rmIL-12 in vivo after the transfer of antigen-stimulated LNC developed a more severe and prolonged course of disease compared with vehicle-treated control animals. In contrast, treatment of mice with an antibody to murine IL-12 after cell transfer completely prevented paralysis, with only 40% of the mice developing mild disease. These results demonstrate that in vitro stimulation of antigen primed LNC with PLP and rmIL-12 enhances their subsequent encephalitogenicity. Furthermore, inhibition of endogenous IL-12 in vivo after LNC transfer prevented paralysis, suggesting that endogenous IL-12 plays a pivotal role in the pathogenesis of this model of autoimmune disease.Keywords
This publication has 20 references indexed in Scilit:
- Interleukin‐12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cellsEuropean Journal of Immunology, 1993
- Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response.The Journal of Experimental Medicine, 1993
- Recombinant interleukin 12 cures mice infected with Leishmania major.The Journal of Experimental Medicine, 1993
- Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells.The Journal of Experimental Medicine, 1993
- Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma.The Journal of Experimental Medicine, 1993
- The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice.The Journal of Experimental Medicine, 1992
- Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrinNature, 1992
- Effect of anti-interferon-γ and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouseJournal of Neuroimmunology, 1992
- Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice.Proceedings of the National Academy of Sciences, 1992
- Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers.The Journal of Experimental Medicine, 1991